Share This Author
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
This review focuses on the evolution of iron chelators from initial lead compounds through to the development of novel chelating agents, many of which show great potential to be clinically applied in the treatment of iron overload disease and cancer.
Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease.
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
- Phatsapong Yingchoncharoen, D. Kalinowski, D. Richardson
- Biology, ChemistryPharmacological Reviews
- 1 July 2016
The current state of lipid-based nanoparticle research is discussed, including the development of liposomes for cancer therapy, different strategies for tumor targeting, liposomal formulation of various anticancer drugs that are commercially available, recent progress in liposome technology for the treatment of cancer, and the next generation of nanoparticles.
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
Detailed investigations of the thiosemicarbazone group of ligands have demonstrated that they are highly effective chelators that, besides RR, also target a range of other molecules including NDRG1 and top2α, all of which contribute to their anticancer effects.
Unraveling the mysteries of serum albumin—more than just a serum protein
The intracellular localization of albumin was assessed in order to understand the mechanisms and pathways responsible for its uptake, distribution and catabolism in multiple tissues, and this is reviewed herein.
2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
This investigation generated the related 2-acetylpyridine thiosemicarbazone (HApT) analogues to examine the influence of the methyl group at the imine carbon and identified structural features necessary to form Fe complexes with potent anticancer activity.
Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond
- Yu Yu, J. Wong, D. Lovejoy, D. Kalinowski, D. Richardson
- Biology, ChemistryClinical Cancer Research
- 1 December 2006
Chelators originally designed to treat disorders of copper overload, such as penicillamine, trientine, and tetrathiomolybdate, have also emerged as potential anticancer drugs, as they are able to target the key angiogenic cofactor, copper.
Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous…
It was demonstrated by EPR spectroscopy that dimeric copper compounds of the type [CuLCl](2), identified crystallographically, dissociate in solution to give monomeric 1:1 Cu:ligand complexes, which represent the biologically active form of the complex.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
A set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes are presented.